Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioCryst Pharmaceuticals, Inc. - Common Stock
(NQ:
BCRX
)
9.655
+0.075 (+0.78%)
Streaming Delayed Price
Updated: 2:58 PM EDT, Jul 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about BioCryst Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
↗
June 06, 2026
BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth...
Via
MarketBeat
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
↗
May 07, 2026
BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.
Via
Benzinga
BioCryst (BCRX) Q1 2026 Earnings Transcript
↗
May 06, 2026
BioCryst (BCRX) Q1 2026 Earnings Transcript
Via
The Motley Fool
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss
↗
May 06, 2026
Via
Chartmill
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat
↗
February 26, 2026
Via
Chartmill
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?
↗
December 12, 2025
Via
Stocktwits
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play
↗
October 14, 2025
Via
Stocktwits
BioCryst To Acquire Astria Therapeutics In $700M Deal
↗
October 14, 2025
Via
Stocktwits
Why Dyne Therapeutics Stock Was Crushing it This Week
↗
November 21, 2025
The company has solid potential with its development of drugs targeting muscle disorders.
Via
The Motley Fool
Topics
Artificial Intelligence
BioCryst (BCRX) Q3 2025 Earnings Call Transcript
↗
November 03, 2025
BioCryst (BCRX) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue
↗
November 03, 2025
BioCryst Q3 2025 results: Earnings beat estimates with $0.06 EPS, but revenue of $159.4M missed forecasts. ORLADEYO sales grew 37%.
Via
Chartmill
Topics
Earnings
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 14, 2025
Via
Benzinga
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
Earnings Outlook For BioCryst Pharma
↗
August 01, 2025
Via
Benzinga
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
↗
November 03, 2025
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
Via
Benzinga
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
↗
October 14, 2025
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth.
Via
Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
October 08, 2025
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...
Via
MarketMinute
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
↗
August 21, 2025
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
Via
Benzinga
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level
↗
August 04, 2025
CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year.
Via
Stocktwits
Topics
Artificial Intelligence
Earnings
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth
↗
August 04, 2025
BioCryst Pharmaceuticals (BCRX) beats Q2 2025 estimates with strong revenue and profit growth, driven by ORLADEYO sales. Shares rise ~5% pre-market.
Via
Chartmill
BioCryst (BCRX) Q2 Revenue Jumps 50%
↗
August 04, 2025
Via
The Motley Fool
BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering
↗
June 27, 2025
BioCryst sells European Orladeyo rights to Neopharmed for up to $264 million, plans to eliminate term debt and boost long-term cash position.
Via
Benzinga
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish
↗
June 27, 2025
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up...
Via
Stocktwits
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
↗
June 03, 2025
BIOCRYST PHARMACEUTICALS (NASDAQ:BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.
Via
Chartmill
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
↗
May 13, 2025
BIOCRYST PHARMACEUTICALS (BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.
Via
Chartmill
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish
↗
May 05, 2025
BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year.
Via
Stocktwits
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
↗
May 05, 2025
BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.
Via
Benzinga
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
↗
May 05, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
May 05, 2025
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
